Article
A test for the optineurin gene will be available to ophthalmologists soon - possibly this year and certainly by 2003, said S. Kumar Chandrasekaran, PhD, CEO of InSite Vision, Alameda, CA.
A new era for MacTel: Clinicians react to FDA approval of revakinagene taroretcel-lwey
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Women’s eye health: The Fred Hollows Foundation's call for change this International Women’s Day
Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus
Australian Society of Ophthalmologists announces new board appointments
Cleveland Clinic’s Cole Eye Institute expands with Jeffrey and Patricia Cole Pavilion